The DOI matches its Crossref record; 290 of the 290 references it cites were found in a registry or an index.
Lipoprotein(a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology
Open accessAbstract
Scanu, and colleagues cloned and sequenced the LPA gene coding for apo(a) (4, 5), a protein with homology to plasminogen, which accounts for the difference between an Lp(a) particle and an LDL particle.These observations generated a huge scientific interest in Lp(a), leading to an exponential growth in the number of articles published, which then later declined again.Renewed interested in Lp(a) came in 2009 from Pia Kamstrup et al. ( 6) with genetic evidence from Mendelian randomization that high Lp(a) is causally associated with cardiovascular disease, from the Emerging Risk Factors Collaboration led by John Danesh that Lp(a) epidemiologically is continuously and independently associated with cardiovascular disease risk (7), and from Robert Clarke et al. (8) that of 2,100 candidate genes for cardiovascular disease, genetic variation in the LPA gene was the strongest genetic cardiovascular risk factor.Following the publication of these studies, high concentrations of Lp(a) have been considered to be a direct cause of cardiovascular disease, just like high LDL cholesterol concentrations.Genetic evidence largely free of confounding and fully free of reverse causation, two major problems of observational epidemiology, is what has cemented the understanding of causality of Lp(a) for cardiovascular disease.These novel and important findings led the European Atherosclerosis Society to publish a 2010 consensus panel statement recommending screening for elevated Lp(a) in individuals at intermediate, high, or very high cardiovascular risk, and suggested a desirable plasma concentration of less than 50 mg/dl (9).Of note, we naturally were fully aware that the risk of cardiovascular disease increases already at Lp(a) levels above 30 mg/dl, but to get the attention of the clinical community, we believed it was the best strategy to start focusing on individuals with the highest cardiovascular risk, that is, the 20% of individuals with concentrations above 50 mg/dl.Abstract Human epidemiologic and genetic evidence using the Mendelian randomization approach in large-scale studies now strongly supports that elevated lipoprotein (a) [Lp(a)] is a causal risk factor for cardiovascular disease, that is, for myocardial infarction, atherosclerotic stenosis, and aortic valve stenosis.The Mendelian randomization approach used to infer causality is generally not affected by confounding and reverse causation, the major problems of observational epidemiology.This approach is particularly valuable to study causality of Lp(a), as single genetic variants exist that explain 27-28% of all variation in plasma Lp(a).The most important genetic variant likely is the kringle IV type 2 (KIV-2) copy number variant, as the apo(a) product of this variant influences fibrinolysis and thereby thrombosis, as opposed to the Lp(a) particle per se.We speculate that the physiological role of KIV-2 in Lp(a) could be through wound healing during childbirth, infections, and injury, a role that, in addition, could lead to more blood clots promoting stenosis of arteries and the aortic valve, and myocardial infarction.Randomized placebo-controlled trials of Lp(a) reduction in individuals with very high concentrations to reduce cardiovascular disease are awaited.Recent genetic evidence documents elevated Lp(a) as a cause of myocardial infarction, atherosclerotic stenosis, and aortic valve stenosis.-Nordestgaard,B. G., and A. Langsted.Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated baseline and on-statin treatment Lp(a) concentration above the 80th percentile of the general population (50 mg/dL) is a strong genetic risk factor for cardiovascular disease independent of LDLC [23,24].”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [23]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Furthermore, several randomized trials have shown that directly infused HDL mimetics increase plasma HDL-C concentrations, but do not reduce the progression of atherosclerosis as measured by intravascular ultrasound [68,69].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [69]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
The metabolic and molecular bases of inherited disease
Chen, Y.-T. (2001) · Medical Entomology and Zoology · Cited by 6,928
Davey Smith, G., & Ebrahim, S. (2003) · International Journal of Epidemiology · doi:10.1093/ije/dyg070 · Cited by 5,882
Mendelian randomization: genetic anchors for causal inference in epidemiological studies
Davey Smith, G., & Hemani, G. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu328 · Cited by 4,677
Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology
Lawlor, D. A., Harbord, R. M., Sterne, J. A. C., Timpson, N., & Davey Smith, G. (2008) · Statistics in Medicine · doi:10.1002/sim.3034 · Cited by 4,618
PEDERSEN, T. R. (2004) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2004.08.027 · Cited by 3,106
Nordestgaard, B. G., Chapman, M. J., Humphries, S. E., Ginsberg, H. N., Masana, L., Descamps, O. S., Wiklund, O., Hegele, R. A., Raal, F. J., Defesche, J. C., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht273 · Cited by 2,761
Self-citationClinical Factors Associated With Calcific Aortic Valve Disease
Stewart, B. F., Siscovick, D., Lind, B. K., Gardin, J. M., Gottdiener, J. S., Smith, V. E., Kitzman, D. W., & Otto, C. M. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(96)00563-3 · Cited by 2,029
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Padmanabhan, A., Connelly‐Smith, L., Aqui, N., Balogun, R. A., Klingel, R., Meyer, E., Pham, H. P., Schneiderman, J., Witt, V., Wu, Y., et al. (2019) · Journal of Clinical Apheresis · doi:10.1002/jca.21705 · Cited by 2,230
Borén, J., Chapman, M. J., Krauss, R. M., Packard, C. J., Bentzon, J. F., Binder, C. J., Daemen, M. J., Demer, L. L., Hegele, R. A., Nicholls, S. J., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz962 · Cited by 1,601
Self-citationKronenberg, F., Mora, S., Stroes, E. S. G., Ference, B. A., Arsenault, B. J., Berglund, L., Dweck, M. R., Koschinsky, M., Lambert, G., Mach, F., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac361 · Cited by 1,449
Self-citation
Metadata
- Authors
- Nordestgaard, B. G., & Langsted, A.
- Affiliations
- University of Copenhagen (DK)
- Corresponding author
- Nordestgaard, Børge G.
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2016-11
- Volume
- 57
- Issue
- 11
- Pages
- 1953-1975
- ISSN
- 0022-2275 (ISSN-L)
- PMC
- PMC5087876
- OpenAlex
- W2526556731
- Cited by
- 575
- References
- 290
- Citations by year
- 2026: 46 · 2025: 66 · 2024: 72 · 2023: 65 · 2022: 72 · 2021: 59 · 2020: 67 · 2019: 60 · 2018: 37 · 2017: 28 · 2016: 2
- FWCI
- 8.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 1410 d)
- Locations
- Journal of Lipid Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- lipoprotein(a), cardiovascular disease, causal risk factors, LPA gene, Mendelian randomization, genetic association, plasminogen homology, aortic stenosis, myocardial infarction, atherosclerotic stenosis, Lp(a) screening, LDL cholesterol, reverse causality, confounding
- MeSH terms
- Aortic Valve Stenosis, Cardiovascular Diseases, Humans, Myocardial Infarction, Risk Factors, Lipoprotein(a), Genetic Predisposition to Disease, DNA Copy Number Variations
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lipoprotein(a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. https://app.cochat.ai/papers/10.1194/jlr.r071233
- The paper
- Nordestgaard, B. G., & Langsted, A. (2016). Lipoprotein(a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. Journal of Lipid Research. https://doi.org/10.1194/jlr.r071233
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.